Clinical Trial Update: TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for NW-101C, a TCR-engineered T cell therapy by Neowise Biotechnology, targeting metastatic solid tumors; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• NW-101C

Snippet

Sponsor: Neowise Biotechnology | Conditions: Solid Metastatic Tumor | Phase 1 | Status: RECRUITING